Bortezomib (BZ) is the first clinically approved proteasome inhibitor that has shown
remarkable anticancer activity in patients with hematological malignancies. However, many …

Expression of the proinflammatory and proangiogenic chemokine IL-8, which is regulated at
the transcriptional level by NF-κB, is constitutively increased in androgen-independent …

Bortezomib enhances T cell apoptosis by inhibiting NF-κB activation, thereby suppressing
cutaneous T cell-dependent inflammatory responses by reducing interferon-γ production …

The proteasome inhibitor bortezomib has been shown to possess promising antitumor
activity and significant efficacy against a variety of malignancies. Different studies …

The proteasome, a key component of the ubiquitin-proteasome pathway, has emerged as an
important cancer therapeutic target. PS-341 (also called Bortezomib or Velcade) is the first …

Given its role in cellular metabolism, the proteasome could prove to be a critical target that
can be exploited in treating cancer. In preclinical studies, several mechanisms for …

Bortezomib is a proteasome inhibitor with remarkable preclinical and clinical antitumor
activity in multiple myeloma (MM) patients. The initial rationale for its use in MM was …

The proteasome inhibitor bortezomib, which induces cell death in various cancer cell lines
including lymphatic neoplasias, has recently been approved for the treatment of relapsed …

Bortezomib is a proteasome inhibitor with proven efficacy in multiple myeloma and non–
Hodgkin's lymphoma. This study reports the effects of bortezomib in B-cell lymphoma cell …

Abstract Background: XPO1 (exportin-1/CRM1) mediates nuclear export of proteins
containing leucine-rich amino-acid consensus sequences. XPO1 cargo proteins include …